Calliditas Therapeutics AB (publ) (CALT) Competitors $40.00 0.00 (0.00%) As of 07/3/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock CALT vs. AKRO, ADMA, PCVX, KRYS, RYTM, CYTK, PTCT, ZLAB, ACAD, and MRUSShould you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include Akero Therapeutics (AKRO), ADMA Biologics (ADMA), Vaxcyte (PCVX), Krystal Biotech (KRYS), Rhythm Pharmaceuticals (RYTM), Cytokinetics (CYTK), PTC Therapeutics (PTCT), Zai Lab (ZLAB), ACADIA Pharmaceuticals (ACAD), and Merus (MRUS). These companies are all part of the "pharmaceutical products" industry. Calliditas Therapeutics AB (publ) vs. Its Competitors Akero Therapeutics ADMA Biologics Vaxcyte Krystal Biotech Rhythm Pharmaceuticals Cytokinetics PTC Therapeutics Zai Lab ACADIA Pharmaceuticals Merus Akero Therapeutics (NASDAQ:AKRO) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation. Does the media refer more to AKRO or CALT? In the previous week, Akero Therapeutics had 5 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 5 mentions for Akero Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Akero Therapeutics' average media sentiment score of 0.33 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Akero Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Akero Therapeutics Neutral Calliditas Therapeutics AB (publ) Neutral Which has stronger earnings and valuation, AKRO or CALT? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkero TherapeuticsN/AN/A-$252.06M-$1.95-26.67Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Is AKRO or CALT more profitable? Akero Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Akero Therapeutics' return on equity of -15.19% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Akero TherapeuticsN/A -15.19% -13.97% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Which has more volatility & risk, AKRO or CALT? Akero Therapeutics has a beta of -0.15, suggesting that its stock price is 115% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Do institutionals & insiders hold more shares of AKRO or CALT? 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 7.1% of Akero Therapeutics shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts prefer AKRO or CALT? Akero Therapeutics presently has a consensus price target of $82.50, suggesting a potential upside of 58.61%. Given Akero Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Akero Therapeutics is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryAkero Therapeutics beats Calliditas Therapeutics AB (publ) on 9 of the 15 factors compared between the two stocks. Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALT vs. The Competition Export to ExcelMetricCalliditas Therapeutics AB (publ)Pharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19B$812.96M$5.56B$9.04BDividend YieldN/A4.84%5.22%3.99%P/E Ratio-21.621.1527.6520.23Price / Sales0.74230.41419.56119.26Price / CashN/A23.4426.2128.59Price / Book37.746.328.035.65Net Income-$43.96M-$27.99M$3.18B$249.15M7 Day PerformanceN/A2.32%2.88%2.91%1 Month PerformanceN/A9.07%1.67%4.11%1 Year Performance2.07%11.51%34.39%20.98% Calliditas Therapeutics AB (publ) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180AKROAkero Therapeutics3.4504 of 5 stars$53.36-5.0%$82.50+54.6%+142.5%$4.48BN/A-27.3630Insider TradeADMAADMA Biologics4.1503 of 5 stars$18.21+0.3%$27.67+51.9%+59.6%$4.34B$426.45M21.42530Positive NewsPCVXVaxcyte1.7706 of 5 stars$32.51-0.2%$136.50+319.9%-57.3%$4.20BN/A-8.15160News CoverageKRYSKrystal Biotech4.5831 of 5 stars$137.46-1.0%$211.13+53.6%-22.4%$4.01B$290.52M33.04210News CoverageAnalyst RevisionRYTMRhythm Pharmaceuticals3.8115 of 5 stars$63.19+0.7%$77.31+22.3%+55.6%$3.99B$130.13M-22.49140News CoverageCYTKCytokinetics3.9282 of 5 stars$33.04-0.4%$70.92+114.7%-38.9%$3.96B$18.47M-6.25250PTCTPTC Therapeutics4.3078 of 5 stars$48.84-2.0%$65.00+33.1%+57.7%$3.95B$806.78M7.501,410Analyst RevisionZLABZai Lab3.4092 of 5 stars$34.97+0.7%$54.28+55.2%+110.3%$3.86B$398.99M-14.041,869News CoverageInsider TradeAnalyst RevisionGap UpACADACADIA Pharmaceuticals4.6273 of 5 stars$21.57-2.5%$27.88+29.2%+29.9%$3.70B$957.80M15.74510MRUSMerus1.8266 of 5 stars$52.60-0.7%$84.64+60.9%+0.9%$3.67B$36.13M-12.8937 Related Companies and Tools Related Companies Akero Therapeutics Alternatives ADMA Biologics Alternatives Vaxcyte Alternatives Krystal Biotech Alternatives Rhythm Pharmaceuticals Alternatives Cytokinetics Alternatives PTC Therapeutics Alternatives Zai Lab Alternatives ACADIA Pharmaceuticals Alternatives Merus Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CALT) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Calliditas Therapeutics AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
